Share

May 13, 2020 "Results are encouraging even if not definitive", according to AIfa, those on Tocilizumab, the Roche drug, usually used to treat rheumatoid arthritis.

The study suggests that it can "significantly" reduce one-month mortality, but that its impact is less relevant on early mortality.

Promoted by the National Cancer Institute of Naples, "in emergency conditions, with high expectations and the absence of effective treatments", explains Aifa, it was the first approved by AIFA during the Covid19 emergency.